ARVN - NASDAQ
Arvinas, Inc.
$7.70
-3.8%Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
At a Glance
Live SnapshotArvinas, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Arvinas, Inc. Balance Sheet
ARVN • NASDAQ
| Arvinas, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
142.9M | 100.5M | 311.7M | 81.3M | 108.3M | 588.4M | 9.2M | 3.2M | 30.9M | 5.1M | |
542.5M | 938.9M | 949.3M | 1.1B | 1.4B | 100.2M | 271.7M | 184.6M | 8.3M | 30.5M | |
685.4M | 1B | 1.3B | 1.2B | 1.5B | 688.6M | 280.9M | 187.8M | 39.2M | 35.6M | |
6.4M | 13.7M | 7.2M | 8M | 25.7M | 8.4M | 6.3M | 5M | 26M | 1.4M | |
1M | 5.7M | 0.0 | 1M | 15M | 1M | 0.0 | 2.8M | 25M | 0.0 | |
5.4M | 8M | 7.2M | 7M | 10.7M | 7.4M | 6.3M | 2.3M | 1M | 1.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 19.7M | 6.1M | 3.7M | 2.8M | 316.9K | 314.8K | |
8.9M | 14.2M | 12M | 26.9M | 4.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
700.7M | 1.1B | 1.3B | 1.2B | 1.6B | 703.1M | 290.9M | 195.7M | 65.5M | 37.3M | |
NON-CURRENT ASSETS | ||||||||||
13.4M | 16M | 14M | 17.8M | 16.6M | 14.3M | 10.7M | 3.6M | 1.3M | 633.8K | |
3.8M | 8.1M | 10.4M | 10.8M | 12.5M | 0.0 | 26.8K | 20.8K | 20.8K | 20.8K | |
17.2M | 24.1M | 24.4M | 28.6M | 29.1M | 14.3M | 10.8M | 3.6M | 1.3M | 654.6K | |
717.9M | 1.1B | 1.3B | 1.3B | 1.6B | 717.4M | 301.6M | 199.3M | 66.8M | 37.9M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
29M | 16.6M | 18.5M | 16M | 31.3M | 7.1M | 4.6M | 2.8M | 596.5K | 1.6M | |
24.2M | 13.4M | 17.8M | 5.7M | 31.3M | 7.1M | 4.6M | 2.8M | 596.5K | 1.6M | |
4.8M | 3.2M | 700K | 10.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 55.2M | 25.7M | 40M | 10.7M | 9.9M | 1.8M | 4M | 3.5M | 1.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 154.5K | 159.3K | 141.2K | |
1.7M | 1.8M | 1.9M | 1.8M | 1.1M | 1M | 673.9K | 0.0 | 0.0 | 0.0 | |
0.0 | 3.2M | 700K | 10.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
71.3M | 156.2M | 163M | 218.6M | 206.2M | 22.2M | 20M | 16.1M | 13.6M | 6.7M | |
40.5M | 0.0 | 48M | 18.7M | 12.4M | 9M | 5.8M | 0.0 | 0.0 | 0.0 | |
142.5M | 229.8M | 257.1M | 295.1M | 261.7M | 49.2M | 32.8M | 23M | 17.9M | 10M | |
NON-CURRENT LIABILITIES | ||||||||||
400K | 600K | 800K | 1M | 1M | 2M | 2M | 2M | 151.1K | 312.6K | |
134.3M | 292M | 386.2M | 405.1M | 534.3M | 22.9M | 38.4M | 37.5M | 48.5M | 3.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -61.4M | -56.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 150K | 50.9K | 56.8K | |
141.5M | 299.9M | 387.5M | 408.8M | 538.2M | 26M | 42.1M | 39.6M | 48.7M | 3.9M | |
8.5M | 9.1M | 2.4M | 4.5M | 4M | 2.1M | 2.4M | 0.0 | 0.0 | 0.0 | |
284M | 529.7M | 644.6M | 703.9M | 799.9M | 75.2M | 75M | 62.6M | 66.6M | 13.9M | |
SHAREHOLDERS' EQUITY | ||||||||||
-91.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 61.5M | 56.9M | |
100K | 100K | 100K | 100K | 0.0 | 0.0 | 38.5K | 31.2K | 1.2M | 947.5K | |
2.1B | 2.1B | 2B | 1.5B | 1.5B | 1.1B | 599.1M | 439.1M | 0.0 | 947.5K | |
-1.6B | -1.5B | -1.3B | -965.4M | -682.9M | -491.9M | -372.6M | -302.3M | -62.4M | -33.8M | |
1.2M | 1M | -3.1M | -19.2M | -4.6M | 600K | 107.6K | -217.7K | -9.8K | -28.7K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -947.5K | |
433.9M | 561.7M | 660M | 564.9M | 781.7M | 642.2M | 226.7M | 136.7M | 245.9K | 24M | |
433.9M | 561.7M | 660M | 564.9M | 781.7M | 642.2M | 226.7M | 136.7M | 245.9K | 24M | |
SUMMARY | ||||||||||
717.9M | 1.1B | 1.3B | 1.3B | 1.6B | 717.4M | 301.6M | 199.3M | 66.8M | 37.9M | |
542.5M | 938.9M | 949.3M | 1.1B | 1.4B | 100.2M | 271.7M | 184.6M | 8.3M | 30.5M | |
8.5M | 9.7M | 3.2M | 5.5M | 5M | 4.1M | 4.4M | 2.2M | 310.4K | 453.8K | |
-134.4M | -90.8M | -308.5M | -75.8M | -103.3M | -584.3M | -4.8M | -1M | -30.6M | -4.6M | |
72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 | 72,644,801 |
SEC Filings
ARVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 10, 2026 | 2026 |
Related Guides
Continue your ARVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.